Estimate survival and risk stratification for metastatic prostate cancer using CHAARTED volume, Gleason score, PSA, and performance status.
Metastatic prostate cancer encompasses a wide spectrum of disease from newly diagnosed hormone-sensitive disease (mCSPC) to heavily pretreated castration-resistant prostate cancer (mCRPC). Prognosis varies enormously based on disease volume, biology, performance status, and treatment history. Landmark trials including CHAARTED, LATITUDE, STAMPEDE, and ENZAMET have transformed survival outcomes by demonstrating the benefit of early combination therapy for hormone-sensitive metastatic disease.
This calculator integrates multiple prognostic factors — ECOG performance status, PSA level, Gleason grade group, disease extent (CHAARTED volume classification), and laboratory markers (ALP, LDH, hemoglobin, albumin) — to provide composite risk stratification with estimated median survival, 2-year, and 5-year survival probabilities. It also provides CHAARTED volume-based treatment recommendations aligned with current NCCN and EAU guidelines.
Risk stratification helps oncologists communicate prognosis, select appropriate treatment intensity, and identify patients who may benefit from clinical trial enrollment. Patients with high-volume or high-risk features benefit most from intensified upfront combination therapies, while those with low-volume disease may have excellent outcomes with sequential treatment approaches.
Metastatic prostate cancer treatment has become increasingly complex with multiple effective combination regimens. Accurate risk stratification helps clinicians match treatment intensity to disease biology — ensuring high-risk patients receive maximally intensive therapy while sparing lower-risk patients unnecessary toxicity. Keep these notes focused on your operational context. Tie the context to the calculator’s intended domain. Use this clarification to avoid ambiguous interpretation.
Composite risk score = ECOG points + PSA points + Gleason points + extent points + lab points. Therapy multiplier adjusts for disease setting (1.0 for mCSPC, 1.3 for mCRPC pre-chemo, 1.8 for mCRPC post-chemo). CHAARTED high volume = ≥ 4 bone metastases OR visceral metastases.
Result: Intermediate risk, median OS ~42 months, 2-year survival ~70%
A newly diagnosed mCSPC patient with ECOG 1, Gleason 4+3, high-volume bone disease, and PSA 45 falls into intermediate risk with an estimated median survival of approximately 42 months with modern combination therapy.
Prior to 2015, treatment for newly diagnosed mCSPC was ADT alone, with additional therapies reserved for castration-resistant disease. CHAARTED (2015) and STAMPEDE revolutionized the field by demonstrating that adding docetaxel to ADT at diagnosis improved overall survival by 13.6 months in high-volume disease. Subsequently, LATITUDE showed abiraterone + ADT improved survival by 16.8 months in high-risk mCSPC. ENZAMET confirmed enzalutamide + ADT benefit. Most recently, PEACE-1 and ARASENS demonstrated triplet therapy benefit, establishing ADT + docetaxel + novel hormone agent as a standard option for high-volume/high-risk disease.
Multiple prognostic models exist: the Halabi model for mCRPC incorporates PSA, LDH, ALP, ECOG, sites of disease, and prior treatment. The LATITUDE high-risk criteria (≥ 2 of: Gleason ≥ 8, ≥ 3 bone mets, visceral metastases) define a population with particular benefit from abiraterone. No single model is universally adopted; this calculator synthesizes multiple validated prognostic factors into a practical composite risk assessment.
Circulating tumor DNA (ctDNA), AR-V7 splice variant detection, PSMA PET quantification, and artificial intelligence-based imaging analysis are emerging as next-generation prognostic biomarkers. Theranostics with 177-Lu-PSMA-617 (VISION trial) has established a new standard of care in later-line mCRPC and may move to earlier disease settings.
Metastatic castration-sensitive prostate cancer (mCSPC) refers to disease that still responds to androgen deprivation therapy (ADT). Metastatic castration-resistant prostate cancer (mCRPC) is disease that progresses despite castrate testosterone levels (< 50 ng/dL). The transition to CRPC represents a critical inflection point in the disease trajectory, with shorter expected survival and different treatment options.
The CHAARTED trial defined high-volume disease as having ≥ 4 bone metastases with at least 1 beyond the axial skeleton (spine/pelvis), OR having visceral metastases (liver, lung, brain, etc.). High-volume disease has significantly worse prognosis and benefits most from upfront combination therapy (ADT + docetaxel ± novel hormone agent) compared to ADT alone.
Higher Gleason scores (grade groups 4-5, Gleason 8-10) indicate more aggressive tumor biology with poorer differentiation and higher proliferation rates. These cancers are more likely to develop castration resistance quickly and metastasize to visceral organs. Gleason 9-10 disease carries the worst prognosis and often requires the most aggressive combination treatment.
Triplet therapy (ADT + docetaxel + novel hormone agent like abiraterone) has shown benefit particularly in high-volume/high-risk mCSPC (PEACE-1, ARASENS). However, it carries increased toxicity. Low-volume disease may be adequately treated with ADT + a novel hormone agent alone. Treatment selection should balance expected benefit against toxicity, considering patient fitness, comorbidities, and preferences.
Homologous recombination repair (HRR) gene testing (BRCA1, BRCA2, ATM, PALB2, etc.) is now standard in mCRPC. BRCA1/2 mutations predict response to PARP inhibitors (olaparib, rucaparib). Microsatellite instability (MSI-H) may predict response to pembrolizumab. Tumor mutational burden and other biomarkers are being studied. These do not replace clinical prognostic factors but add precision to treatment selection.
ALP reflects osteoblastic bone activity and is elevated when prostate cancer metastasizes to bone. Higher ALP levels correlate with greater bone tumor burden and shorter survival. ALP > 200 U/L is an independent adverse prognostic factor across multiple models (Halabi, Armstrong). It can also serve as a treatment response marker — declining ALP often indicates responding disease.